Your browser doesn't support javascript.
loading
Two prolonged viremic SARS-CoV-2 infections with conserved viral genome for two months.
Abu-Raddad, Laith J; Chemaitelly, Hiam; Malek, Joel A; Ahmed, Ayeda A; Mohamoud, Yasmin A; Younuskunju, Shameem; Al Kanaani, Zaina; Al Khal, Abdullatif; Al Kuwari, Einas; Butt, Adeel A; Coyle, Peter; Jeremijenko, Andrew; Kaleeckal, Anvar Hassan; Latif, Ali Nizar; Shaik, Riyazuddin Mohammad; Abdul Rahim, Hanan F; Yassine, Hadi M; Al Kuwari, Mohamed G; Al Romaihi, Hamad Eid; Al-Thani, Mohamed H; Bertollini, Roberto.
Afiliación
  • Abu-Raddad LJ; Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University,
  • Chemaitelly H; Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University,
  • Malek JA; Genomics Laboratory, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar; Department of Genetic Medicine, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
  • Ahmed AA; Genomics Laboratory, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
  • Mohamoud YA; Genomics Laboratory, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
  • Younuskunju S; Genomics Laboratory, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
  • Al Kanaani Z; Hamad Medical Corporation, Doha, Qatar.
  • Al Khal A; Hamad Medical Corporation, Doha, Qatar.
  • Al Kuwari E; Hamad Medical Corporation, Doha, Qatar.
  • Butt AA; Hamad Medical Corporation, Doha, Qatar.
  • Coyle P; Hamad Medical Corporation, Doha, Qatar.
  • Jeremijenko A; Hamad Medical Corporation, Doha, Qatar.
  • Kaleeckal AH; Hamad Medical Corporation, Doha, Qatar.
  • Latif AN; Hamad Medical Corporation, Doha, Qatar.
  • Shaik RM; Hamad Medical Corporation, Doha, Qatar.
  • Abdul Rahim HF; College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
  • Yassine HM; Biomedical Research Center, Qatar University, Doha, Qatar; Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar.
  • Al Kuwari MG; Primary Health Care Corporation, Doha, Qatar.
  • Al Romaihi HE; Ministry of Public Health, Doha, Qatar.
  • Al-Thani MH; Ministry of Public Health, Doha, Qatar.
  • Bertollini R; Ministry of Public Health, Doha, Qatar.
Infect Genet Evol ; 88: 104684, 2021 03.
Article en En | MEDLINE | ID: mdl-33352320
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Viremia / ARN Viral / Genoma Viral / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Infect Genet Evol Asunto de la revista: BIOLOGIA / DOENCAS TRANSMISSIVEIS / GENETICA Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Viremia / ARN Viral / Genoma Viral / SARS-CoV-2 / COVID-19 / Anticuerpos Antivirales Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Female / Humans / Male Idioma: En Revista: Infect Genet Evol Asunto de la revista: BIOLOGIA / DOENCAS TRANSMISSIVEIS / GENETICA Año: 2021 Tipo del documento: Article